All Articles

This study examined characteristics of the Patient Care Connect Program team as an exemplar given their demonstrated success in improving patient health and care experience while lowering costs of care through patient navigation.

Nurse Navigator Debra Kelly describes her team’s experience in determining content and designing a guide to educate patients and improve their experience.

When elotuzumab was given in combination with pomalidomide, bortezomib, and dexamethasone (elo-PVD), patients with multiple myeloma refractory to prior treatment demonstrated encouraging responses, according to data from a phase 2 trial presented at the 2019 ASH Annual Meeting by Andrew Yee, MD, from Massachusetts General Hospital Cancer Center in Boston.

In patients with multiple myeloma who were pomalidomide naive and refractory to lenalidomide, an alloral combination of selinexor, pomalidomide, and dexamethasone (SPd) led to a median progression-free survival (PFS) of 12.2 months and an overall response rate (ORR) of 56%, with 19% of patients achieving very good partial responses.

In patients with transplant-ineligible, newly diagnosed multiple myeloma, adding daratumumab to bortezomib, melphalan, and prednisone (D-VMP) continues to improve overall survival (OS) and progression-free survival (PFS) when compared with bortezomib, melphalan, and prednisone (VMP) alone.

Following induction therapy with daratumumab (DARA) plus cyclophosphamide, bortezomib, and dexamethasone (CyBorD), monthly daratumumab maintenance therapy given for a year continued to improve depth of response in a group of patients with newly diagnosed or relapsed multiple myeloma.

In patients with relapsed or refractory multiple myeloma, the efficacy benefits seen when elotuzumab was added to lenalidomide/dexamethasone (Ld) were achieved without negatively affecting health-related quality of life (HRQoL).

After more than 4 years of follow-up, the addition of daratumumab to lenalidomide and dexamethasone (D-Rd) continues to significantly improve progression-free survival (PFS) in patients with relapsed or refractory multiple myeloma, according to an update of the phase 3 POLLUX study. Patients on D-Rd also demonstrated deeper responses than patients who received lenalidomide and dexamethasone (Rd) alone.

In patients with newly diagnosed multiple myeloma, treatment with weekly daratumumab plus carfilzomib, lenalidomide, and dexamethasone (KRd) resulted in an “unprecedented” minimal residual disease (MRD) negativity rate of 77% without stem cell transplantation.

Payers and hospital systems can benefit tremendously through enhanced patient experience, clinical outcomes, and return on investment that navigation programs provide.